Date Added: 20/03/2017

Date Updated: 20/03/2017

Ipilimumab (Yervoy) for unresectable malignant melanoma in paediatric patients

Specialties: Oncology & radiotherapy

Technology Type: Drugs

Stage of development: Experimental - pilot or phase II

Stage of EAA: Prioritised for assessment

Description, patients and keywords:

Indication

Malignant Melanoma.

Subgroup

Paediatric patients (aged 12 to <18 years old).

Stage of disease

Unresectable stage III/IV.

Place in Treatment

First line or previously treated.

This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.